

Alsiver, J. (2016). Big Pharma Innovation in Small Places. Fortune.com. Haettu: <http://fortune.com/2016/05/13/big-pharma-biotech-startups/>.

Barroso, L. (2011). The Problems and the Controls of the New Administrative State of the EU. The London School of Economics and Political Science, PhD thesis submitted to the Department of Law.

Bluhm, M. (2019). The Role of Monopoly in America's Prescription Drug Crisis. Open Markets.

Brown, A. (2013). Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation. *The Journal of Law, Medicine & Ethics*, 41(3), 611-619.

Brown, H. (2007). Sweetening the pill. *British Medical Journal*, 334(7595), 664-666.

Committee on Oversight and Reform, U.S. House of Representatives. (2021). Drug Pricing Investigation - Industry Spending on Buybacks, Dividends, and Executive Compensation. *Staff Report*, July.

Cosgrove, L., & Wheeler, E. E. (2013). Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines. *The Journal of Law, Medicine & Ethics*, 41(3), 644-653.

Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020). FDA Approval and Regulation of Pharmaceuticals, 1983-2018. *JAMA*, 323(2), 164-176.

Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017). Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. *British Medical Journal*, 359, j4530.

Drummond, R. (2007) When evidence isn't: Trials, Drug companies and the FDA. *Journal of Law & Policy*, 15 (3).

Gagnon, M.-A. (2013). Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health. *The Journal of Law, Medicine & Ethics*, 41(3), 571-580.

Garattini, S. and Bertele', V. (2002). Efficacy, safety, and cost of new anticancer drugs. *British Medical Journal*, 325, 269-71.

Hofmarcher, T., Lindgren, P., Wilking, N., & Jönsson, B. (2020). The cost of cancer in Europe 2018. *European Journal of Cancer*, 129, 41-49.

Institute for Health & Socio-Economic Policy. The R&D smokescreen: the prioritization of marketing & sales in the pharmaceutical industry: IHSP; 2016.

Jorgensen, P. D. (2013). Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda. *The Journal of Law, Medicine & Ethics*, 41(3), 561-570.

Ledley, F. D., McCoy, S. S., Vaughan, G., & Cleary, E. G. (2020). Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies. *JAMA*, 323(9), 834-843.

Light, Donald et al. (2013). Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. *Journal of Law, Medicine & Ethics*. 41(3), 590-600.

Mazzucato, M. (2015). How taxpayers Prop Up Big Pharma, and how to cap that. *Los Angeles Times*. October 27th.

Olson, M. K. (2002). Pharmaceutical Policy Change and the Safety of New Drugs. *The Journal of Law and Economics*, 45(S2), 615-642.

Rodwin, M. A. (2013). Five Un-Easy Pieces of Pharmaceutical Policy Reform. *The Journal of Law, Medicine & Ethics*, 41(3), 581-589.

Rose, S. L. (2013). Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness. *The Journal of Law, Medicine & Ethics*, 41(3), 680-687.

Song, F., Parekh, S., Hooper, L., Loke, Y. K., Ryder, J., Sutton, A. J., Hing, C., Kwok, C. S., Pang, C., & Harvey, I. (2010). Dissemination and publication of research findings: an updated review of related biases. *Health technology assessment*, 14(8), iii-193.

Vilamoska A, & Conklin, A. (2009). Improving patient safety: Addressing Patient Harm Arising from Medical Error. *Policy Insight*, 3(2).

Vokinger, K. N., Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2017). Strategies That Delay Market Entry of Generic Drugs. *JAMA internal medicine*, 177(11), 1665-1669.